1. Home
  2. LYRA vs CSCI Comparison

LYRA vs CSCI Comparison

Compare LYRA & CSCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LYRA
  • CSCI
  • Stock Information
  • Founded
  • LYRA 2005
  • CSCI 1990
  • Country
  • LYRA United States
  • CSCI Canada
  • Employees
  • LYRA N/A
  • CSCI N/A
  • Industry
  • LYRA Medical/Dental Instruments
  • CSCI
  • Sector
  • LYRA Health Care
  • CSCI
  • Exchange
  • LYRA Nasdaq
  • CSCI NYSE
  • Market Cap
  • LYRA 13.5M
  • CSCI 11.1M
  • IPO Year
  • LYRA 2020
  • CSCI 1996
  • Fundamental
  • Price
  • LYRA $0.19
  • CSCI $3.00
  • Analyst Decision
  • LYRA Buy
  • CSCI
  • Analyst Count
  • LYRA 5
  • CSCI 0
  • Target Price
  • LYRA $4.50
  • CSCI N/A
  • AVG Volume (30 Days)
  • LYRA 1.9M
  • CSCI 9.5K
  • Earning Date
  • LYRA 11-12-2024
  • CSCI 11-12-2024
  • Dividend Yield
  • LYRA N/A
  • CSCI N/A
  • EPS Growth
  • LYRA N/A
  • CSCI N/A
  • EPS
  • LYRA N/A
  • CSCI N/A
  • Revenue
  • LYRA $1,471,000.00
  • CSCI $4,834,000.00
  • Revenue This Year
  • LYRA N/A
  • CSCI N/A
  • Revenue Next Year
  • LYRA N/A
  • CSCI N/A
  • P/E Ratio
  • LYRA N/A
  • CSCI N/A
  • Revenue Growth
  • LYRA 3.37
  • CSCI N/A
  • 52 Week Low
  • LYRA $0.16
  • CSCI $2.50
  • 52 Week High
  • LYRA $6.79
  • CSCI $11.10
  • Technical
  • Relative Strength Index (RSI)
  • LYRA 46.20
  • CSCI N/A
  • Support Level
  • LYRA $0.18
  • CSCI N/A
  • Resistance Level
  • LYRA $0.22
  • CSCI N/A
  • Average True Range (ATR)
  • LYRA 0.02
  • CSCI 0.00
  • MACD
  • LYRA -0.00
  • CSCI 0.00
  • Stochastic Oscillator
  • LYRA 16.31
  • CSCI 0.00

About LYRA Lyra Therapeutics Inc.

Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.

About CSCI COSCIENS BIOPHARMA INC

Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries. The company is engaged in the development of therapeutic assets and proprietary extraction technology.

Share on Social Networks: